Last reviewed · How we verify
NiCord
At a glance
| Generic name | NiCord |
|---|---|
| Sponsor | Gamida Cell ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS (PHASE3)
- Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies (PHASE3)
- Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients
- Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies (PHASE1, PHASE2)
- Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies (PHASE1, PHASE2)
- Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NiCord CI brief — competitive landscape report
- NiCord updates RSS · CI watch RSS
- Gamida Cell ltd portfolio CI